Skip to main content
    E

    Enveric Biosciences Inc (ENVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.44
    -0.08 (-4.95%)

    Market Cap: $6.78M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Enveric Biosciences Inc (ENVB) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Enveric Biosciences are Ensysce Biosciences (ENSC), Longeveron LLC (LGVN) and NuCana (NCNA). By market cap, Enveric Biosciences ranks 7th of the 13 companies on this page; Biovie (BIVI) is the largest at $12.12M.

    Peer Comparison

    ENVB's revenue growth of -7.3% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Enveric Biosciences (ENVB)$6.78MN/A0.2x0.0%N/A-7.3%0.00%
    Ensysce Biosciences Inc (ENSC)$8.14MN/A1.2x-280.5%-260.6%-15.1%0.00%
    Longeveron LLC (LGVN)$8.40MN/A5.9x0.0%N/A-9.2%0.00%
    NuCana PLC (NCNA)$3.88MN/AN/A0.0%N/A0.0%0.00%
    Exicure Inc (XCUR)$7.07MN/AN/A0.0%N/A928.0%0.00%
    Skye Bioscience, Inc. Common Stock (SKYE)$4.83MN/AN/A0.0%-3685.3%0.0%0.00%
    Aprea Therapeutics Inc (APRE)$5.91MN/AN/A0.0%N/A-98.4%0.00%
    VistaGen Therapeutics Inc (VTGN)$8.01MN/A3.4x0.0%N/A-46.5%0.00%
    Biovie Inc (BIVI)$12.12MN/AN/A0.0%N/A0.0%0.00%
    Cadrenal Therapeutics, Inc. Common Stock (CVKD)$5.39MN/AN/A0.0%N/A0.0%0.00%
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)$4.02MN/AN/A0.0%-247.2%0.0%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    CNS Pharmaceuticals Inc (CNSP)$4.22MN/AN/A0.0%N/A0.0%0.00%
    Peer median$6.49MN/A3.4x0.0%-260.6%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Enveric Biosciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Ensysce Biosciences Inc (ENSC)
    Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs.
    ENSC competitors
    Longeveron LLC (LGVN)
    Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions.
    LGVN competitors
    NuCana PLC (NCNA)
    NuCana plc, a clinical-stage biopharmaceutical company, is dedicated to the development of products for the treatment of cancer.
    NCNA competitors
    Exicure Inc (XCUR)
    Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases...
    XCUR competitors
    Skye Bioscience, Inc. Common Stock (SKYE)
    Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops...
    SKYE competitors
    Aprea Therapeutics Inc (APRE)
    Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor...
    APRE competitors
    VistaGen Therapeutics Inc (VTGN)
    VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential...
    VTGN competitors
    Biovie Inc (BIVI)
    BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States.
    BIVI competitors
    Cadrenal Therapeutics, Inc. Common Stock (CVKD)
    Cadrenal Therapeutics, Inc. (CVKD) is a clinical-stage biopharmaceutical firm dedicated to developing groundbreaking therapies for renal diseases and associated...
    CVKD competitors
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)
    Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
    LIMN competitors
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    CNS Pharmaceuticals Inc (CNSP)
    CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central...
    CNSP competitors

    Frequently Asked Questions About ENVB

    Who are Enveric Biosciences' main competitors?

    The companies most similar to Enveric Biosciences include Ensysce Biosciences (ENSC), Longeveron LLC (LGVN), NuCana (NCNA), Exicure (XCUR) and Skye Bioscience, Inc. Common Stock (SKYE), listed from the closest match.

    Who is Enveric Biosciences' biggest competitor?

    Biovie (BIVI) is the largest of the similar companies at $12.12M; Ensysce Biosciences (ENSC) is the closest match by business profile, size, sector and industry.

    How does ENVB stock compare with its competitors?

    ENVB's P/S is 0.2x against a peer median of 3.4x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Enveric Biosciences' competitors pays a higher dividend?

    Enveric Biosciences pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Enveric Biosciences bigger than its competitors?

    No. Enveric Biosciences is 7th by market cap among the 13 companies on this page; the largest is Biovie (BIVI) at $12.12M.